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induced cardiac injury in rat through down
regulation of inflammatory response
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Background: The importance of doxorubicin (Dox), as a potent antitumor antibiotic, is limited by the development
of life-threatening cardiomyopathy. It has been shown that free radicals are involved in acute doxorubicin-induced
toxicity. The aim of this study was to determine the protective effect of vitamin E and telmisartan in acute
doxorubicin induced cardiotoxicity.
Methods: Thirty two male Sprague - Dawly rats were involved in this study and were randomly separated into 4
groups, eight rats in each group, one group received normal saline I.P as control and second group received
doxorubicin 20 mg/kg I.P, the other two groups also received doxorubicin 20 mg/kg I.P as single dose after seven
cumulative doses (for seven days) of vitamin E (100 mg/kg) and telmisartan (1 mg/kg) respectively.
Immunofluorescent staining for monocytes infiltration and analyses of plasma by (ELISAs) for MCP-1and troponin I.
Western immunoblotting assay for ICAM-1, while left ventricular function was analyzed by microcatheter, also
estimated the level of oxidative stress parameters (MDA and Catalase) and cardiac enzymes activities (CK-MB and
LDH) before starting drugs treatment and after treatment period by 48 hours.
Results: The immunofluorescent staining showed that administration of vitamin E and telmisartan are attenuated
of mononuclear cell infiltration; (p < 0.05 vs. Dox group), also reduced the level of chemokines MCP-1 and ICAM-1
expression compared with Dox group only, and there is marked reduction of myocardial troponin-I levels with
improved LV function in vitamin E and telmisartan treated group. Doxorubicin treatment increased MDA, LDH,
CK-MB levels significantly (P < 0.01), and were counteracted by administration of vitamin E and telmisartan, but did
not significantly affect serum catalase activity.
Conclusions: Antioxidant effect (Vitamin E and telmisartan) have been shown to decrease
doxorubicininduced cardiotoxicity.Background
Doxorubicin (Dox) is a cytotoxic anthracycline antibiotic
isolated from cultures of Streptomyces peucetius var.
caesius, and is commonly used in the treatment of a
wide range of cancers, including hematological malig-
nancies, many types of carcinoma, and soft tissue sarco-
mas [1]. A number of different mechanisms have been
proposed for the antitumor action of Dox these include
doxorubicin interacts with DNA by intercalation and
inhibition of macromolecular biosynthesis [2,3], this* Correspondence: Nasser.alemeerat@ucdenver.edu
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reproduction in any medium, provided the orinhibits the progression of the enzyme topoisomerase II,
which relaxes supercoils in DNA for transcription, Dox
stabilizes the topoisomerase II complex after it has bro-
ken the DNA chain for replication, and preventing the
DNA double helix from being resealed and thereby stop-
ping the process of replication [4].
The therapeutic value of Dox as anticancer antibio-
tic is limited by its acute as well as accumulative dose
related cardiotoxicity and by 1967, it was recognized
that Dox could produce fatal cardiac toxicity [5], cur-
rently, there is no specific therapeutic strategy against
this severe disease, and cardiac transplantation remains
a vital option for patients with end-stage Dox-induced
heart failure [6]. The pathogenesis of Dox-inducedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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involve various signaling mechanisms including free
radical stress, calcium overloading, mitochondrial dys-
function dysregulation of iron haemostasis [7], alteration
in beta-adrenergic receptor signaling [8], mitochondrial
dysfunction [9], and activation of matrix metalloprotei-
nase [10]. Also it is notable that, cytokine release
mediated by activation of the innate immune system
is believed to be involved in the pathogenesis of
Dox-induced cardiotoxicity [11], the Free radicals and
other toxic non-radicals generated by anthracyclines can
be neutralized by increasing endogenous antioxidants or
by introducing exogenous antioxidants through nutri-
tional supplements, these interventions may prevent or
attenuate the side-effects of anthracyclines these anti-
oxidants, including vitamins especially (Vitamin A and
provitamin A carotenoids, Vitamin C, Vitamin E) coen-
zyme Q and carnitine can be derived from the diet. In
general, these compounds do not interfere with anthra-
cycline activity in tumor cells.
Our hypothesis is focus on the effective role of vitamin
E and telmisartan in attenuated doxorubicin induced
cardiotoxicity in rat through down regulation of inflam-
matory response.
Methods
Male Sprague - Dawly rats, acclimatized in a quarantine
room for 2 weeks, and all experiments were approved by
the Animal Care and Research Committee of the Uni-
versity of Colorado Denver, and this investigation con-
forms to the Guide for the Care and Use of Laboratory
Animals (National Research Council, revised 1996). The
animals divided in to 4 groups, eight rats in each group,
control groups (normal saline injected I.P) and group
treated with 20 mg/kg doxorubicin in a single injection
intraperitoneal i.p. and other two groups one received
vitamin E (100 mg/kg) [12] orally by N/G tube for one
week followed by doxorubicin (20 mg/kg) I.P as single
dose, and the other one received telmisartan (1 mg/kg)
[13] orally by N/G tube for one week followed by doxor-
ubicin (20 mg/kg) I.P as single dose.
Left ventricular function analysis
Pressure-volume loop and hemodynamic analysis
was planned for all animals as described previously by
N.Yousif,2011 [14], in briefly the animals anesthetized
with ketamin in dose of 50 mg/kg injected intraperitoneal
and neck was opened longitudinally and right common
carotid artery exposed and freed, ligated distally and stay
suture placed proximally, then small opening was made in
artery and size 1 F-micro tipped pressure transducer cathe-
ter (Millar Instruments, Houston, TX, USA) was inserted
into the LV lumen via the right carotid artery for measure-
ment of LV pressure, volume, function and relatedparameters. Then after about 20 minutes of data recording,
the abdomen is opened by right sub costal incision to
reach the inferior vena cava. To acutely change the cardiac
preload, caval occlusion was produced over a 3-s period
using a nonmetallic occluder applied to the IVC. The data
were recorded as a series of pressure-volume loops.
P van software (Conductance Technologies, San Anto-
nio, TX, and Millar, Houston, TX) was used to analyze
all pressure-volume loop data. Regression analyses of
multiple isochronal pressure-volume loop data were pro-
duced by IVC compression. From the baseline and IVC
compression loops, comprehensive sets of hemodynamic
parameters were calculated. All steady-state and caval
occlusion pressure-volume loops were acquired with the
computer data acquisition system. From these data we
selected the following parameter: LV diameters were
measured at end diastole (LVEDD) and end systole
(LVESD), ejection fraction (EF), heart rate (HR), LV sys-
tolic pressure in the ends of both systole and diastole
(LVESP, LVEDP), Cardiac Output (CO) and the maxi-
mum elasticity (Emax).
Animal scarification
After complete assessed the pressure volume loop, the
animal was sacrificed, starting by injection of equal
volume of thiopental and heparin intraperotonealy in
doses ranging from 300 μl to 600 μl for each one, after
giving good time for the animal to go into deep anesthe-
sia, the rat is positioned and taped and the chest is
opened in flap like manner revealing the heart then a
needle of the syringe is introduced into right ventricle to
aspirate around 0.5 ml of blood for plasma analysis.
Immunofluorescent staining
Immunofluorescent staining was performed as described
previously [14]. Myocardial cryosections (5 μm thick)
were treated with a mixture of 30% methanol and 70%
acetone and fixed in 4% paraformaldehyde. Sections
were incubated with blocking solution (10% BSA in PBS)
for 45 min. Sections were then incubated with a mixture
of rat monoclonal antibody against mouse neutrophil
marker protein (Clone 7/4; ABD Serotec, Oxford, UK)
and rabbit polyclonal antibody against mouse macrophage
marker protein CD68 (Santa Cruz Biotechnology, Santa
Cruz, CA), 5 μg/ml each in antibody buffer, for 90 min.
Sections were then incubated for 45 min with a mixture of
Cy3-labeled goat anti-rat IgG (labeling neutrophils red;
1:250 dilution with antibody buffer) and Alexa488-
conjugated goat anti-rabbit IgG (labeling macrophages
green; 1:400 dilution with antibody buffer). Sections were
counterstained with Alexa Fluor 350-labeled wheat germ
agglutinin (for outlining myocardial cells). To assess the
staining specificity, adjacent sections were incubated with a
mixture of nonimmune rat IgG and nonimmune rabbit
Table 1 Selected average parameters from pressure-volume loop study in vivo assessment of left ventricular function
are expressed as mean±SEM
Variables Control Dox Vitamin E Telmisartan P value
End-systolic Volume (uL) 43.64 ± 1.23 69.61 ± 2.36 51.34 ± 1.22 <0.05
End-diastolic Volume (uL) 69.61 ± 2.37 85.03 ± 3.53 63.21 ± 1.43 <0.05
End-systolic Pressure (mmHg) 70.57 ± 1.22 56.64 ± 6.76 64.65 ± 1.75 <0.05
End-diastolic Pressure (mmHg) 8.36 ± 1.19 3.42 ± 0.36 7.14 ± 1.54 <0.05
Ejection Fraction (%) 42.34 ± 3.21 17.35 ± 0.57 25.43 ± 1.21 <0.05
Cardiac Output (ml/min) 12.67 ± 1.26 6.03 ± 0.4 7.83 ± 1.17 <0.51
E MAX 21.38 ± 2.36 14.34 ± 1.32 16.43 ± 1. <0.51
P< 0.05, statistically differences between Dox treated only group and with Vitamin E, and Telmisartan treatment; (n = 8 per group).
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the primary antibodies and then processed in identical
conditions. Microscopic observation and photography
were performed with a Leica DMRXA digital microscope.
Images were analyzed using Slide Book 2.6 software to
obtain quantitative estimates of area.Blood sample
The collected blood from each rat was centrifuged (in
10000 RPM, for 10 minutes at 4 °C) and the yielded plasma
samples was obtained before starting drug treatment (at
zero time) and after 48 hours of completion treatment (i.e.
after 9 days) for determination of serum malondialdehyde
(MDA) Level (the byproduct of lipid peroxidation); Serum
Catalase Activity (CAT enzyme); Serum Creatine kinase
(CK-MB) enzyme level and Serum Lactate dehydrogenase
(LDH) enzyme level.*
Figure 1 Immunofluorescent staining demonstrates that Dox treatme
than vitamin E and telmisartan group. Data are expressed as mean± SEEnzyme-linked immunosorbent assays (ELISAs)
Myocardial MCP-1 and troponin I were measured using
commercially available ELISA kits (R and D Systems)
according to the manufacturer's instructions.Western immunoblotting assay
Myocardial tissue was homogenized with a rotor-stator
homogenizer and treated in PBS containing 0.5% Triton X-
100 and a protease inhibitor cocktail. Size fraction of crude
protein (20 μg) was performed by electrophoresis. After
transfer, the membrane was incubated in PBS 5% nonfat
dry milk to block nonspecific binding. The membrane was
then incubated for 60 minutes with an antibody against
ICAM-1, at 1:1000 to 1:2000 dilutions with PBS containing
0.05% Tween 20 and 5% dry milk. After thorough washes,
the membrane was treated with peroxidase-labeled sec-
ondary antibody (1:5000 dilutions with phosphate-buffered#
nt only group of rat exhibit greater macrophages infiltration










Figure 2 Dysfunctions of the coronary endothelium as well as injury to cardiac muscle cells are the consequences of Dox effect among
many factors, MCP-1and ICAM-1 expression are released into the myocardium and circulation. Data are expressed as mean± SEM, (A)
MCP-1 #*P < 0.05; vs. Dox only (n = 8 per group). (B) While the representative western blots showing increased ICAM-1 protein expression in Dox
only group #*P < 0.05; vs. Dox only (n = 8 per group).
*
#
Figure 3 Cardiac troponin I is very sensitive and specific
indicators of damage to the heart muscle (myocardium).
in this figure the level of troponin I is significantly reduction in
group of Dox + antioxidants agents; Data are expressed as
mean± SEM, #*P < 0.05; vs. Dox only only (n = 8 per group).
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minutes. Protein bands were developed using enhanced
chemiluminescence technique. Densitometry was per-
formed using a computerized densitometer (Molecular
Dynamics, Sunnyvale, CA).
Statistical analysis
The data were expressed as mean +/− standard deviation
(SD) were calculated and compared using ANOVA test.
Significance was set at p < 0.05 for all comparisons
unless otherwise stated. Statistical analysis has been
done by using paired t-test and ANOVA test. Significant
difference was set at P < 0.05 [15].
Results
Vitamin E and telmisartan improves LV function
To determine the degree of heart injury after Dox injec-
tion with and without antioxidant agents, we measured
LV function in vivo by assessing pressure-volume loops
using a micro-conductance catheter. Hemodynamic data
are shown in (Table 1). Dox injected only group show
displayed impaired systolic and diastolic (LVP, LVEDP,
CO), and antioxident agent treated group show improved
in the LV function.
Vitamin E, and telmisartan have a reduced myocardial
macrophages accumulation
Dox only treated rat group displayed significantly
enhanced infiltration of macrophages compared to anti-
oxident agent treated rat group as in Figure 1.Reduced level of cytokines MCP-1 and ICAM-1 expression
in vitamin E, and telmisartan treated group
To characterize the cardiac inflammatory response due
to the myocardial toxicity by doxorubicin injection, we
measured cardiac chemokines (MCP-1 and ICAM-1),
that showed an increased expression of them in the
group treated with doxorubicin only compared to Vita-
min E, and Telmisartan as in Figure 2.
Table 2 Effect of doxorubicin, Vitamin E, and Telmisartan on rat serum MDA in μmol/L
Groups MDA level (μmol/L) Precent of changing
Before treatment After treatment
Doxorubicin 15 mg./kg 3.27 ± 0.52 14.8 ± 0.45 †† 352%
Doxo. + Vit E 100 mg./kg 2.98 ± 0.29 7.87 ± 0.99 †† ** 164%
Doxo. + Telmisartan1mg/kg. 3.17 ± 0.29 11.1 ± 0.37 †† ** 249.2%
The values are expressed as mean ± SEM. † P< 0.05, †† P < 0.01 (means of each group after treatment versus their means before treatment) by using paired t test.
* P < 0.05, ** P < 0.01 (means of Vitamin E, and Telmisartan groups after treatment versus means of Doxorubicin group after treatment) by using LSD test.
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telmisartan treated group
Cardiac troponin I is indicators of cardiac injury, raised
troponin level are prognostically important in many of
the conditions in which they are used for diagnosis. In
present study showed significant reduction in Vitamin E,
and Telmisartan treated group after a single dose injec-
tion of doxorubicin, and this reflected that the cardiac
injury is more in the group treated with doxorubicin
only, as shown in Figure 3.Significant reduction in MDA and CK-MB in group treated
with vitamin E and telmisartan
Dox injected result in a significant elevation of MDA
from 3.27 ± 0.52 to 14.8 ± 0.45 (P < 0.01) .The calculated
% of increment in MDA was 352%. Treatment with vita-
min E and Telmisartan have resulted in significant
reduction in doxorubicin induced MDA elevation, the
percent of change in MDA was 160% and 249.2% respec-
tively compared to 352% with doxorubicin alone. There
was statistically significant differences (P < 0.05) in the
means of serum CK-MB level between the doxorubicin
group and other two groups treated by vitamin E and
Telmisartan as shown in Table 2. Dox lead to a signifi-
cant elevation of CK-MB level from 685.8 ± 115.4 to
4759.1 ± 137.7 with percentage of rise of 594% compared
to baseline value. Vitamin E and Telmisartan treatment
prevented the elevation in CK-MB level induced by DOX.
with percentage of rise of 71.7%, and 189% respectively
compared to DOX. percentage of rise of 594%. There was
statistically significant differences (P < 0.05) in the means
of serum CK-MB level between the doxorubicin group
and other two groups treated by Vitamin E, and Telmi-
sartan as shown in Table 3.Table 3 Effect of Doxorubicin, Vitamin E, and Telmisartan on
Groups CK-MB
Before treatment
Doxorubicin 15 mg./kg 685.8 ± 115.4
Doxo. + Vit E 100 mg./kg 587.6 ± 116.2
Doxo. + Telmisartan 1 mg./kg 666.7 ± 146.1
The values are expressed as mean ± SEM.† P< 0.05, †† P < 0.01 (means of each grou
* P < 0.05, ** P < 0.01 (means of Vitamin E, and Telmisartan groups after treatment vVitamin E, and telmisartan prevented the elevation in
LDH level induced by DOX treatment
Dox has resulted in a significant elevation of LDH level
from 578.8 ± 72.3 to4328.1 ± 209.5 with percentage of
rise of 647% compared to baseline value (P < 0.01). Vita-
min E, and Telmisartan prevented the elevation in LDH
level induced by Dox treatment with percentage of rise
of 155%, and 444% respectively compared to Dox per-
centage of rise of 647%. There was statistically significant
differences (P < 0.05) in the means of serum LDH level
between the doxorubicin group and other two groups
treated by Vitamin E, and Telmisartan as shown in
Table 4.
No significance increased in serum catalase level between
the doxorubicin group and other two groups treated by
vitamin E, and telmisartan
Serum catalase enzyme decreased slightly after treat-
ment in all group, however this reduction did not reach
statistical significant differences P > 0.05 in the means of
serum catalase level between the doxorubicin group and
other two groups treated by Vitamin E, and Telmisartan
as shown in Table 5.
Discussion
Adriamycin (also called doxorubicin) induces cardiotoxi-
city through many pathways one of the most accepted
mechanisms is through formation of the free radicals.
These free radicals cause membrane and macromole-
cules damage which directly lead to myocardial damage
[16]. Under normal physiological conditions, the tissue
concentration of FORs is limited due to the existence of
a delicate balance between the generation of PRFO and
the antioxidant defense system [17]. However, if thisrat serum CK-MB in IU/L
level IU/L Percent of changing
After treatment
4759.1 ± 137.7 †† 594%
1008.7 ± 181.9 ** 71.7%
1926.2 ± 155.4 ††** 189%
p after treatment versus their means before treatment) by using paired t test.
ersus means of Doxorubicin group after treatment) by using LSD test.
Table 4 Effect of Doxorubicin, Vitamin E, and Telmisartan on rat serum LDH in IU/L
Groups LDH level IU/L Percent of changing
Before treatment After treatment
Doxorubicin 15 mg./kg 578.8 ± 72.3 4328.1 ± 209.5 ††** 647%
Doxo. + Vit E 100 mg./kg 585.1 ± 51.4 1494.9 ± 55.1†† ** 155%
Doxo. + Telmisartan 1 mg./kg 570.4 ± 31.9 3108.5 ± 248.9 ††** 444%
The values are expressed as mean ± SEM. † P< 0.05, †† P < 0.01 (means of each group after treatment versus their means before treatment) by using paired t test.
* P < 0.05, ** P < 0.01 (means of Vitamin E, and Telmisartan groups after treatment versus means of Doxorubicin group after treatment) by using LSD test.
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through an enhanced production or via a reduction in
the endogenous antioxidant defense system or both, the
heart is at risk for PRFO-mediated myocardial cell
damage. Thus, changes in myocardial antioxidant status
and oxidative stress may have profound effects on car-
diac structure and function [18]. In the present study,
using vitamin E and telmisartan as antioxidant, the
hearts of rats treated with Dox only showed increased
level of TNF-activation. Furthermore, our data showed
reduces in level of MCP-1 and ICAM-1 with antioxidant
agent and this decrease in the proinflammatory cyto-
kines and chemokines activity may be caused by the dis-
turbances in the innate immune system mainly in TLR
family as described by other [19]. Moreover, in present
work, the vitamin E and telmisartan treated group signif-
icantly improved LV function compared with Dox
injected only group and this confirmed by other study
that showed significantly depressed cardiac function in
Dox rat model [20]. Cardiac troponin I (cTnI) is a sensi-
tive and specific marker of myocardial injury, the results
of the rats injected with Dox and antioxidants agent
showed marked reduction in the level of plasma cardiac
troponin I and histopathological changes induced by Dox
injection only showed more myocardial injury with
marked infiltration of monocyte and cellular changes, this
coincided with the work of other authors who reported
marked granular blood cells in the wide pericapillary space
between the disorganized cardiac myocytes [13].
The MDA levels were significantly elevated after a single
dose of doxorubicin, this increase in MDA level can be
attributed to that the hydroxyl radicals (OH•) greatly
enhances the NADH-dependent microsomal lipid peroxi-
dation and thus initiates a lipid radical chain reaction
causing oxidative damage to cell membranes. MDA wasTable 5 Effect of Doxorubicin, Vitamin E, and Telmisartan on
Groups Catalas
Before treatment
Doxorubicin 15 mg./kg 0.06 ± 0.005
Doxo. + Vit E 100 mg./kg 0.055 ± 0.004
Doxo. + Telmisartan 1 mg./kg 0.057 ± 0.002
The values are expressed as mean ± SEM. † P< 0.05, †† P < 0.01 (means of each gro
* P < 0.05, ** P < 0.01 (means of Vitamin E, and Telmisartan groups after treatment vsignificantly decreased after vitamin E treatment, this can
be explained by that vitamin E allows free radicals to
abstract a hydrogen atom from the antioxidant molecule
rather than from poly unsaturated fatty acids, thus break-
ing the chain of free radical reaction; also MDA was sig-
nificantly decreased after telmisartan treatment, this can
be explained by that reactive oxygen species (ROS) are
involved in many of the Ang II signaling pathways [21].
LDH activity significantly decreased after antioxidants
agent treatment, Przybyszewski et al, 1994, reported that
vitamin E diminished the MDA and the activity of LDH
and CPK in the serum of gamma irradiated rats due to
free radicals scavenging effect, also [22] mention that the
reduction in activity of serum LDH in animals treated
with telmisartan may be due to the suppression of cardiac
injury by AT1 receptor antagonism.
Our study showed that increased significantly in the CK-
MB activity after doxorubicin treatment this increase in
activity of CK-MB indicates an injury or damage to cardiac
cells by doxorubicin which may be due to the inhibition of
nucleic acid and protein synthesis [23]. Sridharan & Shya-
madevi 2002 [24], attributed the increase of CK-MB to the
excessive production of free radicals and lipid peroxides
that might have caused leakage of cytosolic enzymes and
to membrane cell damage [25,26], and this CK-MB activity
decreased after antioxidants treatment also this mention
by other study [3,27]Serum catalase level did not signifi-
cantly changed after doxorubicin, vitamin E, and telmisar-
tan treatment which may be due to that catalase and other
antioxidant enzymes other than GPx have been shown to
be relatively less sensitive to oxidative stress [28-30].
Conclusions
Antioxidant effect (Vitamin E, and telmisartan) have been
shown to decrease doxorubicin-induced cardiotoxicity asrat serum catalase in IU/L





up after treatment versus their means before treatment) by using paired t test.
ersus means of Doxorubicin group after treatment) by using LSD test.
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http://www.biomedcentral.com/1471-2261/12/63indicated by their ability to decrease the cytokines,MCP-1,
ICAM-1and increment in serum MDA level, LDH and
CK-MB, and also there is no change in the animals charac-
teristic at the end of the protocol, this experimental work
need further investigation to know the exact pathway of
antioxidant in attenuated Dox induce cardiac injury.
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